Breaking News, Trials & Filings

Trials & Filings in Brief: Oct. 31, 2013

Ariad, Baxter, e-Therapeutics, Hyperion, Kamada, Mesoblast, Stem Cell Therapeutics, Teva

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I Kamada reports preliminary pediatric diabetes data . . . read more Phase II e-Therapeutics starts trial of tramadol CR formulation . . . read more Phase III Teva gets approval for CHF trial . . . read more Post-Approval Hyperion begins UCD outcomes study . . . read more Filings Ariad suspends Iclusig marketing in U.S. . . . read more Baxter submits Rixubis in EU . . . read more Stem Cell Therapeutics gets Orphan status for tigecycline in AML . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters